Intec Pharma Announces New Research Collaboration Agreement with MSD

Intec Pharma | October 08, 2020

Intec Pharma Ltd. ("Intec" or "the Company") today announces it has entered into a new research collaboration agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth, NJ, USA. Details of the agreement are confidential. "We are very excited to continue to work with MSD," said Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma. "This new agreement builds upon the relationship we have enjoyed in prior research and allows the companies to leverage their combined experience in delivery."

Spotlight

Emerging Pharma, a leading healthcare group based in Malaysia, is focused on bringing the world's best healthcare products to Southeast Asia.

Spotlight

Emerging Pharma, a leading healthcare group based in Malaysia, is focused on bringing the world's best healthcare products to Southeast Asia.

Related News

CNS Pharmaceuticals Announces US Drug Manufacturing Milestones

CNS Pharmaceuticals | September 03, 2020

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, today provides an update on progress for the U.S. manufacturing of Berubicin, the Company's lead drug candidate, in preparation for upcoming clinical trials. As previously announced, the Company implemented a dual-track drug product manufacturing strategy and engaged U.S.-based Pharmaceutics International, Inc. ("Pii") and Italy-based BSP Pharmaceuticals S.p.A. ("BSP") for the production of Berubicin. By engaging two separate manufacturers on two separate continents, CNS expects to mitigate COVID-19-related delay risks, diversify its supply chain and provide for localized availability of Berubicin.

Read More

PHARMACY MARKET

IMI Releases Tamper Evident Caps with DoseID Certified RFID

International Medical Industries, Inc. | February 28, 2022

IMI bolsters expertise in secure drug delivery products with the release of new Prep-Lock Tamper Evident Cap for ENFit® and Oral Syringes with incorporated Radio Frequency Identification (RFID) technology. IMI's Prep-Lock line of Tamper Evident Products helps ensure medication safety from pharmacy to patient. The DoseID certified RFID Technology presents an opportunity to augment the proven benefits of tamper-evident products. "RFID technology represents the future of inventory management and medication safety. This technology aligns perfectly with IMI's core business strategy of providing drug security solutions to healthcare institutions worldwide," says Bryan McGurn IMI Senior Vice President of Sales & Marketing. Prep-Lock Tamper Evident Caps are an established method for providing safeguards to ensure medication safety. Tamper Evident Caps for ENFit and Oral Syringes offer the same high-value risk mitigation as the IV Caps utilized by 84% of the top outsource compounders in the US. RFID technology enables real-time scanning that optimizes inventory management, efficiency, and medication safety while creating quantifiable pharmaceutical supply chain benefits by providing item-level inventory visibility. Every drug secured with a Tamper Evident Cap featuring RFID is trackable throughout its entire lifecycle. These two powerful technologies in combination enhance workflow efficiencies, eliminate time-consuming manual inventory control processes, provide assistance with growing regulatory demand, and supply a comprehensive strategy to prevent, detect, and resolve drug diversion events. In addition, Tamper Evident Caps with incorporated RFID technology offer a significant reduction in RFID implementation costs. IMI joined DoseID, a consortium of RFID proponents in 2020 to support the interoperability, quality, and performance of RFID tagged products. The DoseID RFID tag, now incorporated in the Prep-Lock Tamper Evident Cap, is certified by Auburn University RFID Lab's ARC Program to ensure the high standards set by the DoseID consortium are met and that those standards meet the needs of the healthcare industry. "We're using RFID tags to automate some of our inventory management and get better insight into inventory movement," says Dr. Paul Stranges, PharmD, BCACP, AE-C Clinical Assistant Professor at the Department of Pharmacy Practice at The University of Chicago's College of Pharmacy. "It really helps our efficiency." Incorporating RFID technology in IMI's Tamper Evident Cap delivers a significant advantage in supply chain management. They offer both hospitals and outsource compounding operations an efficient and cost-saving method for applying RFID benefits to their drug preparations.

Read More

PHARMA TECH

LEO Pharma and Veeva Systems Partner for Digital Patient-Centered Trials

LEO Pharma | September 30, 2021

LEO Pharma , a global leader in medical dermatology, and Veeva Systems announced a strategic technology partnership to enable scalable digital trials, paperless and patient-centered. Building on its success with the Veeva Clinical Operations suite, LEO Pharma will complete its standardization on existing Veeva clinical technology, be an early adopter of future Veeva solutions, and help shape the Veeva digital trials roadmap. By adopting technology and optimized business processes, LEO Pharma plans to achieve the following goals while maintaining the highest standards in data accuracy, regulatory compliance and patient safety: Significant improvement in the patient experience Increased patient diversity through decentralized trials Greater precision of clinical data 25% reduction in the cost of clinical trials 25% reduction in clinical trial time LEO Pharma will use the integrated suite of Veeva clinical products, including eTMF, CTMS, CDMS, Site Connect, eConsent, ePRO, Virtual Visits and eSource. We were exploring ways to transform clinical trials, but COVID-19 has accelerated this process. By responding quickly to changing market dynamics, we allowed our testing to continue without delay. The partnership with Veeva supports our 2030 strategy because it will help us deliver innovative treatments to patients faster while supporting a more sustainable business. Veeva's results in terms of product excellence make it the ideal long-term partner to help us achieve this goal, which allows us to help patients better and faster. - Jörg Möller, Executive Vice President and Head of R&D at LEO Pharma. We are excited and honored to extend our long-standing partnership with LEO Pharma to be an early adopter of our comprehensive digital testing platform, We intend to help the industry move forward with a scalable digital trials platform that dramatically improves the clinical trial process for patients, sites and sponsors. - Peter Gassner , Founder and CEO of Veeva About Veeva Systems Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence and customer success, Veeva has more than 1,000 customers, from the world's largest pharmaceutical companies to emerging biotechnology companies. As a public benefit company, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders and the industries it serves. About LEO Pharma LEO Pharma helps people achieve healthy skin. The company is a leader in the field of medical dermatology, with a strong R&D portfolio, a wide range of therapies and a pioneering spirit. Founded in 1908 and majority-owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advancing the science of dermatology, setting new standards of care for people with skin diseases. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 93 million patients in 130 countries. In 2020, the company achieved net sales of 1,359 million euros.

Read More